ReviewOncogene2026
Repositioning osteocytes as integrative regulators of breast cancer bone metastasis.
Review in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer bone metastasis remains a major clinical challenge, yet the mechanisms governing metastatic dormancy, reactivation and osteolytic progression within the bone metastatic niche remain incompletely understood. Although the osteoblast-osteoclast 'vicious cycle' has long provided a foundational framework for explaining tumour-induced bone destruction, it does not fully account for several defining features, including prolonged metastatic latency, heterogeneous relapse timing and sensitivity to mechanical and systemic cues. Here, we propose an osteocyte-centred perspective that complements established tumour-bone interaction models by considering osteocytes as integrative regulators of bone niche state. As the most abundant, long-lived and mechanosensitive cells in bone, osteocytes are well positioned to coordinate biomechanical, endocrine, inflammatory and metabolic signals over time. Emerging evidence suggests that osteocyte functional state may influence whether the bone microenvironment remains relatively stable or becomes more permissive for metastatic progression: physiologically intact osteocytes are associated with niche stability and dormancy-supportive conditions, whereas stressed, apoptotic or senescent osteocytes are linked to osteoclast activation, inflammatory remodelling and osteolytic outgrowth. We synthesise recent findings suggesting that osteocytes may participate across multiple stages of bone metastasis, from niche conditioning and dormancy regulation to reactivation and osteolytic progression, through reciprocal crosstalk with tumour cells involving mechanotransduction, cytokine signalling and extracellular vesicle-mediated communication. We also emphasise the current limitations of the evidence base, particularly in relation to pre-metastatic niche formation, organotropism and EV-associated regulatory mechanisms. Rather than displacing existing models, this framework aims to connect mechanobiology, osteoimmunology, endocrine signalling and remodelling dynamics within a stage-aware view of metastatic progression. By repositioning osteocytes as active components of the bone metastatic niche, this review highlights testable concepts for understanding skeletal metastatic dynamics and for informing strategies aimed at stabilising a tumour-restrictive bone microenvironment.
Identifiers
42426271What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.